Esentra 120mg Injection

Esentra 120mg Injection is a doctor prescribed injection that used to treat osteoporosis in postmenopausal women and men at high fracture risk, as well as bone loss associated with hormone therapies for breast or prostate cancer, long-term glucocorticoid use, multiple myeloma, and bone metastases. Esentra 120mg Injection contains contains 120mg of Denosumab that improves overall bone health.

Esentra 120mg Injection is a chemical salt based anticancer medication.Therefore,it has several common side effects like any other medicine.Consult your doctor, if side effects persist for longer period of time.
● Musculoskeletal pain
● Pain in extremities
● Headache
● Constipation
● Rash
● Nerve pain
● Back pain
● Joint pain
● Abdominal discomfort
● Urinary tract infection
● Respiratory tract infection
● Hair loss
● Eczema
● Injection site reactions
● Osteonecrosis of the jaw
● Hypocalcemia

Esentra 120mg Injection is administered subcutaneously, depending on the cancer stage. Patients should not self-administer; it must be injected by a doctor or trained nurse. Consult a doctor for precise dosage and timing.

Esentra 120mg Injection contains 120mg of denosumab( a monoclonal antibody) works by binding to RANK ligand (RANKL), a protein essential for osteoclast formation, function, and survival. Esentra 120mg Injection reduces bone resorption, increases bone mineral density, and strengthens bone structure in osteoporosis or cancer-related to bone loss.

• Pageau, S. C. (2009, May). Denosumab. In MAbs (Vol. 1, No. 3, pp. 210-215). Taylor & Francis.
• Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., ... & Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361(8), 756-765.
• Hanley, D. A., Adachi, J. D., Bell, A., & Brown, V. (2012). Denosumab: mechanism of action and clinical outcomes. International journal of clinical practice, 66(12), 1139-1146.
• Sheedy, K. C., Camara, M. I., & Camacho, P. M. (2015). Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocrine Practice, 21(3), 275-279.